• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

byJinny TsangandAlisha Yi
April 22, 2025
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM.

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

Tags: apixabancancerefficacypulmonary embolismrctsafetyvenous thromboembolism (VTE)
Previous Post

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

Next Post

Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas

RelatedReports

Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation
Pharma

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

August 20, 2025
Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

August 14, 2025
#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer
StudyGraphics

#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer

August 8, 2025
Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients
Gastroenterology

mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial

August 7, 2025
Next Post

Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

Levodopa for Parkinson’s disease more effective than newer generation therapies

Exenatide does not slow Parkinson’s disease progression compared to placebo

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
  • Lilly Strikes $1.3 Billion GPCR Drug Discovery Pact with Superluminal
  • 2 Minute Medicine Rewind August 18, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.